FDA Approved New Potency Assay for Ryoncil Therapy
The newly cleared testing method aims to ensure consistent product quality for Mesoblast's cell-based treatment.
Updated on Sept. 24, 2026 in Biotech
Live Poll
Do you believe recent company-specific regulatory approvals make now a good time to invest?
The FDA approved a new T-cell Proliferation Inhibition BioAssay (TIBA) to monitor the potency of Ryoncil, a treatment for steroid-refractory acute graft versus host disease. This regulatory clearance provides a new tool for verifying product stability during manufacturing.
Why it matters
Updating testing processes is critical for maintaining consistent quality in complex cell therapies as companies scale up production. This approval allows for more sensitive detection of potency changes, which is essential for ensuring patient safety and treatment efficacy.
The newly approved T-cell Proliferation Inhibition BioAssay will function alongside existing testing protocols to monitor the potency of Ryoncil batches. It provides improved sensitivity for detecting fluctuations in product quality during manufacturing scale-up or facility transitions.
The players
FDA
The United States federal agency responsible for regulating biological products, medical devices, and clinical trial oversight.
Mesoblast
A biotechnology company focused on developing off-the-shelf allogeneic cell therapies, including Ryoncil and rexlemestrocel-L.
The details
The T-cell Proliferation Inhibition BioAssay, or TIBA, is designed to measure how well the MSC (mesenchymal stem cell) therapy suppresses T-cell activity, a mechanism central to treating graft versus host disease—a condition where donor cells attack the recipient's body. By providing higher sensitivity than prior release tests, the assay enables more precise monitoring of biological potency. This technical improvement is specifically intended to validate consistency during the transition to larger manufacturing scales or new production facilities.
Timeline
September 24, 2026: The FDA officially approved the new Ryoncil potency assay.
The Tech Race
This regulatory update follows the industry-wide focus on establishing standardized, sensitive potency assays for complex cell-based treatments. As Mesoblast attempts to broaden the use of Ryoncil to other inflammatory conditions, these manufacturing benchmarks become central to competing with other emerging regenerative medicine platforms.
This development standardizes the production monitoring for children 2 months and older currently receiving Ryoncil therapy. While patients will not experience a change in clinical workflow, the upgrade supports the long-term reliability and availability of the treatment across medical facilities.
The takeaway
This assay approval provides a critical quality gate for Mesoblast's lead product as it navigates manufacturing scale-up. Investors and clinicians should monitor further clinical data as the firm attempts to apply this platform to the pipeline candidate rexlemestrocel-L.
Further reading
For broader trends in manufacturing standards, see the Biotech section.
Live Poll
Do you believe recent company-specific regulatory approvals make now a good time to invest?
